Eam Investors, LLC Chinook Therapeutics, Inc. Transaction History

Eam Investors, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Jul 12, 2023	SELL	$21.53 - $26.8 $7.21 Million - $8.97 Million	-334,860 Reduced 87.26%	48,875 $1.13 Million
Q1 2023 May 12, 2023	BUY	$21.53 - $26.8 $6.07 Million - $7.55 Million	281,728 Added 276.18%	383,735 $8.88 Million
Q4 2022 Feb 14, 2023	SELL	$18.63 - $27.35 $408,052 - $599,047	-21,903 Reduced 17.68%	102,007 $2.67 Million
Q3 2022 Nov 14, 2022	BUY	$17.51 - $23.37 $174,066 - $232,321	9,941 Added 8.72%	123,910 $2.44 Million
Q2 2022 Aug 12, 2022	BUY	$12.59 - $18.8 $1.43 Million - $2.14 Million	113,969 New	113,969 $1.99 Million

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Eam Investors, LLC, based on Form 13F filings with the SEC.

Stay updated on Eam Investors, LLC with notifications on news.